GLAND PHARMA Financial Statement Analysis
|
||
The Revenues of GLAND PHARMA have increased by 31.51% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has increased by 22.17 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]
Consolidated | Mar2021 | Mar2020 |
---|---|---|
Revenues | ₹3,463 Cr | ₹2,633 Cr |
Expenses | ₹2,161 Cr | ₹1,678 Cr |
Operating Profit (Excl OI) | ₹1,302 Cr | ₹955 Cr |
Other Income | ₹135 Cr | ₹139 Cr |
Interest | ₹3.41 Cr | ₹7.18 Cr |
Depreciation | ₹99 Cr | ₹95 Cr |
Profit Before Tax | ₹1,335 Cr | ₹993 Cr |
Profit After Tax | ₹997 Cr | ₹773 Cr |
Consolidated Net Profit | ₹997 Cr | ₹773 Cr |
Earnings Per Share (Rs) | ₹60.94 | ₹49.88 |
PAT Margin (%) | 28.79 | 29.35 |
ROE(%) | 20.97 | 21.29 |
ROCE(%) | 28.00 | 27.39 |
Total Debt/Equity(x) | 0.00 | 0.00 |
Key Financials |
||
Market Cap | : | ₹ 42,402.8 Cr |
Revenue (TTM) | : | ₹ 4,400.7 Cr |
Net Profit(TTM) | : | ₹ 1,211.7 Cr |
EPS (TTM) | : | ₹ 73.6 |
P/E (TTM) | : | 35.0 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAND PHARMA | -4.7% | -8.6% | -27.2% |
SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -1.3% | 22.7% |
DIVIS LABORATORIES | 0.4% | 4.2% | -18.1% |
DR REDDYS LABORATORIES | -0.1% | 6.1% | -19% |
CIPLA | 3.4% | -2.8% | -4.2% |
PIRAMAL ENTERPRISES | 3.2% | -3.5% | -29.5% |
CADILA HEALTHCARE | 2.6% | 2.6% | -43.5% |
TORRENT PHARMACEUTICALS | 1.4% | 3.9% | -1.9% |
ALKEM LABORATORIES | 2.7% | -1.9% | -4.2% |
GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]
Y-o-Y | 31.51 % |
5 Yr CAGR | 31.51 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2021 | ₹3,463 Cr | 31.51 | |
Mar2020 | ₹2,633 Cr | - |
GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]
Y-o-Y | 36.29 % |
5 Yr CAGR | 36.29 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2021 | ₹1,302 Cr | 36.29 | |
Mar2020 | ₹955 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 3.67 % |
5 Yr CAGR | 3.67 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2021 | 37.61% | 3.67 | |
Mar2020 | 36.28% | - |
GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]
Y-o-Y | 29.00 % |
5 Yr CAGR | 29.00 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2021 | ₹997 Cr | 29.00 | |
Mar2020 | ₹773 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -1.91 % |
5 Yr CAGR | -1.91 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2021 | 28.79 % | -1.91 | |
Mar2020 | 29.35 % | - |
GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]
Y-o-Y | 22.17 % |
5 Yr CAGR | 22.17 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2021 | ₹61 | 22.17 | |
Mar2020 | ₹50 | - |
GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]
Y-o-Y | 2.23 % |
5 Yr CAGR | 2.23 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2021 | 28% | 2.23 | |
Mar2020 | 27.39% | - |
GLAND PHARMA Share Price vs Sensex
Current Share Price | : | ₹2,574.6 |
Current MarketCap | : | ₹ 42,402.8 Cr |
Updated EOD on | : | Jul 06,2022 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | -4.7% |
-8.6% |
-27.2% |
SENSEX | -0.1% |
-4.7% |
1.2% |
GLAND PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.2% | -1.2% | -14.9% |
S&P BSE ALLCAP | -0% | -4.4% | 0.1% |
S&P BSE 500 | -0% | -4.3% | -0.1% |
S&P BSE LARGE MIDCAP | -0.1% | -4.2% | 0.3% |
S&P BSE 250 LARGEMIDCAP | -0.1% | -4.3% | 0.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MNC | 1.4% | -0.4% | 2.5% |
NIFTY NEXT 50 | 1% | -2.5% | -3.1% |
NIFTY PHARMA | 0.2% | -1.5% | -14.5% |
NIFTY 100 EQUAL WEIGHT | 0.1% | -3.2% | -1.8% |
NIFTY500 MULTICAP 50:25:25 | 0% | -4.7% | -0.7% |
You may also like the below Video Courses
FAQ about GLAND PHARMA Financials
How the annual revenues of GLAND PHARMA have changed ?
The Revenues of GLAND PHARMA have increased by 31.51% YoY .
How the Earnings per Share (EPS) of GLAND PHARMA have changed?
The Earnings Per Share (EPS) of GLAND PHARMA has increased by 22.17 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs
